The TSH secretion in the human pituitary adenomas

Trouillas, Jacqueline; Girod, C; Loras, B; Bruno, Claudio; Sassolas, G.; Perrin, G; Buonaguidi, Roberto

doi:10.1016/s0344-0338(88)80019-0

Cited by 30 publications

(16 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inside these large tumors, 50% of which exceeded 15 mm in diameter and which were radiologically invasive in more than 50% of cases, histological examination confirmed that nuclear atypies and mitoses were frequent, as has been noted previously (2,11). Mitoses alone proved insufficient to evaluate the potential proliferation of the pituitary adenomas.…”

Section: Discussionsupporting

confidence: 84%

“…Finally, some 30% of cases in the clinical series involve associated secretion of other hormones, notably growth hormone (GH) and prolactin (PRL) (9). This is in agreement with findings from anatomopathological series, in which thyrotropic adenomas have frequently proved plurihormonal (2).…”

Section: Introductionsupporting

confidence: 85%

“…In one case, on both light and electron microscopy, two separate cell populations appeared to underly the double secretion. In the other tumors, secretion colocalization was accompanied by a monomorphic cellular appearance under the electron microscope, as reported elsewhere in the literature (2,28). Colocalized TSH-GH or TSH-PRL secretion and the monomorphic cellular appearance found in most tumors suggests that some multipotent cell underlies the tumor process (18).…”

supporting

confidence: 79%

“…They are rare tumors, with a prevalence rate of only 1 : 1 000 000 in the population as a whole, and represent between just 0.2 and 2.8% of all pituitary adenomas (1)(2)(3)(4). Two reviews of the literature documented 69 cases in 1987 (5) and 280 cases 10 years later (6).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Mono- and plurihormonal thyrotropic pituitary adenomas: pathological, hormonal and clinical studies in 12 patients

Bertholon-Grégoire

Trouillas

Guigard

et al. 1999

European Journal of Endocrinology

View full text Add to dashboard Cite

In a series of 12 patients (eight women and four men, aged between 20 and 62 years), operated on for a pituitary adenoma shown to be thyrotropic by immunocytochemistry, we performed a retrospective and comparative analysis of clinical and biological data, tumor studies including immunocytochemistry with double labeling, and proliferation marker (proliferative cell nuclear antigen (PCNA) and Ki-67) detection, electron microscopy and culture. Our study leads us to confirm that thyrotropic tumors are rare (12 of 1174 pituitary adenomas: 1%). The main points arising were that: (1) high or normal plasma TSH associated with an increase in plasma a-subunit and high thyroid hormone levels is the best criterion for diagnosis; (2) the failure of TSH to respond to TRH or Werner's test is not a reliable criterion for diagnosis; (3) thyrotropic adenomas may be 'silent', without clinical signs of hyperthyroidism and with only slight increase in TSH, tri-iodothyronine and thyroxine concentrations; (4) mitoses and nuclear atypies are frequently detected in large tumors, which are invasive in more than 50% of cases -the first analysis of two proliferation markers (PCNA and Ki-67) bears out the relative aggressiveness of thyrotropic adenomas; (5) thyrotropic adenomas are frequently plurihormonal. Immunocytochemical double labeling, complemented by in vitro study, showed that thyrotropic tumor cells sometimes can or sometimes cannot cosecrete TSH, GH or prolactin. The pathological identification of monohormonal and plurihormonal adenomas seems to be supported by clinical and biological differences.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Introductionsupporting

confidence: 85%

supporting

confidence: 79%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Mono- and plurihormonal thyrotropic pituitary adenomas: pathological, hormonal and clinical studies in 12 patients

Bertholon-Grégoire

Trouillas

Guigard

et al. 1999

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…This case was described elsewhere [2]. Some reports indicate that sometimes TSH expression of pituitary adenomas is not accompanied by the disturbance of TSH secretion leading to hyperthyroidism [3,4]. It is also known that GH-secreting tumours in patients with acromegaly are often plurihormonal and express, besides growth hormone (GH), also prolactin and/or TSH [5,6].…”

Section: Introductionmentioning

confidence: 94%

„Cicha” ekspresja tyreotropiny (TSH) w akromegalii i klinicznie nieczynnych gruczolakach przysadki

Pawlikowski

Pisarek

Jaranowska

et al. 2016

Endokrynologia Polska

View full text Add to dashboard Cite

Introduction: The pituitary adenomas secreting thyrotropin (TSH) are considered the rarest type of hormonally active pituitary tumour. In spite of that, many cases are described in the literature. On the other hand, the observations of the co-expression of TSH with other pituitary hormones (mostly with growth hormone [GH]) and "silent" expression of TSH in clinically non-functioning pituitary adenomas (CNFPA) are rather scarce. Materials and methods: Among 93 examined pituitary adenomas, 22 of them were diagnosed as active acromegaly and 71 as clinically non-functioning pituitary adenomas (CNFPA). All of them were immunostained with antibodies against pituitary hormones, including the anti-TSH antibody. TSH-immunopositive adenomas are immunostained also to detect somatostatin receptor subtypes (SSTR 1-5). Results: TSH immunopositivity was found in 4.2% of CNFPA (3/71 tumours) and in 13.6% (3/22) cases of somatotropinomas manifesting as active acromegaly. All of the examined TSH-immunopositive adenomas expressed SSTR subtypes except SSTR4. The symptoms of hyperthyroidism were not observed in any of the acromegalic patients co-expressing TSH with GH. Conclusions: Our data confirm the relative rarity of TSH expression or co-expression of TSH in pituitary tumours. In most cases TSH is co-expressed with GH in patients with acromegaly and is not accompanied by hyperthyroidism. The "silent" expression of TSH may occur also, although rarely in CNFPA. The strong expression of SSTR in TSH-immunopositive CNFPA ("silent thyrotropinoma") indicates the possibility of the treatment of these tumours with somatostatin analogues. (Endokrynol Pol 2016; 67 (5): 515-518)

show abstract

Cytokeratin distribution and functional properties of growth hormone-producing pituitary adenomas

et al. 1994

View full text Add to dashboard Cite

The TSH secretion in the human pituitary adenomas

Cited by 30 publications

References 11 publications

Mono- and plurihormonal thyrotropic pituitary adenomas: pathological, hormonal and clinical studies in 12 patients

Mono- and plurihormonal thyrotropic pituitary adenomas: pathological, hormonal and clinical studies in 12 patients

„Cicha” ekspresja tyreotropiny (TSH) w akromegalii i klinicznie nieczynnych gruczolakach przysadki

Cytokeratin distribution and functional properties of growth hormone-producing pituitary adenomas

Contact Info

Product

Resources

About